Simcere Pharmaceutical Group (SMHGF.PK), Wednesday announced expected revenue and profit for the fiscal year 2025 based on a preliminary assessment of the unaudited consolidated management accounts.
The Group expects revenue of approximately RMB 7,700 million to RMB 7,800 million for the full year, up approximately 16.0% to 17.6% as compared to the revenue of approximately RMB 6,635 million in the previous year.
Moreover, it anticipates to record profit attributable to equity shareholders of the company of approximately RMB 1,300 million to RMB 1,400 million, up approximately 80.1% to 93.9% from last year's approximately RMB 722 million.
Simcere's stock closed at $1.96 on the OTC Markets.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.